Trial · NCT01574716
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 2: Radiologic Progression-free Survival (PFS) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 18.7 | 95% Confidence Interval 11.6 to 27.4 | weeks | |
| Part 2: Radiologic Progression-free Survival (PFS) | Part 2: Placebo + Gemcitabine/Docetaxel | 24.1 | 95% Confidence Interval 11.1 to 36.1 | weeks | |
| Part 2: Symptomatic Progression-free Survival | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 18.1 | 95% Confidence Interval 11.3 to 24.0 | weeks | |
| Part 2: Symptomatic Progression-free Survival | Part 2: Placebo + Gemcitabine/Docetaxel | 24.0 | 95% Confidence Interval 10.7 to 36.1 | weeks | |
| Part 2: Overall Survival (OS) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 18.3 | 95% Confidence Interval 16.2 to 21.1 | months | |
| Part 2: Overall Survival (OS) | Part 2: Placebo + Gemcitabine/Docetaxel | 21.1 | 95% Confidence Interval 14.2 to NA | months | |
| Part 2: Overall Response Rate (ORR) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 19.4 | percentage of participants | ||
| Part 2: Overall Response Rate (ORR) | Part 2: Placebo + Gemcitabine/Docetaxel | 20.0 | percentage of participants | ||
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 12 weeks | 57.6 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: Placebo + Gemcitabine/Docetaxel | 12 weeks | 61.8 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 24 weeks | 43.3 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: Placebo + Gemcitabine/Docetaxel | 24 weeks | 51.0 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 48 weeks | 24.5 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: Placebo + Gemcitabine/Docetaxel | 48 weeks | 25.2 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 52 weeks | 20.8 | percentage of participants | |
| Part 2: Radiologic Progression-free Survival Rate (PFR) | Part 2: Placebo + Gemcitabine/Docetaxel | 52 weeks | 21.4 | percentage of participants | |
| Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels | Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel | 0 | participants | ||
| Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels | Part 2: Placebo + Gemcitabine/Docetaxel | 0 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01574716/results